| Literature DB >> 28562118 |
Pathricia V Tilstam1, Dake Qi1,2, Lin Leng1, Lawrence Young1, Richard Bucala1.
Abstract
INTRODUCTION: Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine with chemokine-like functions that increasingly is being studied in different aspects of cardiovascular disease. MIF was first identified as a proinflammatory and pro-survival mediator within the immune system, and a second structurally related MIF family member, D-dopachrome tautomerase (a.k.a. MIF-2), was reported recently. Both MIF family members are released by myocardium and modulate the manifestations of cardiovascular disease, specifically in myocardial ischemia. Areas covered: A scientific overview is provided for the involvement of MIF family cytokines in the inflammatory pathogenesis of atherosclerosis, myocardial infarction, and ischemia-reperfusion injury. We summarize findings of experimental, human genetic and clinical studies, and suggest therapeutic opportunities for modulating the activity of MIF family proteins that potentially may be applied in a MIF allele specific manner. Expert opinion: Knowledge of MIF, MIF-2 and their receptor pathways are under active investigation in different types of cardiovascular diseases, and novel therapeutic opportunities are being identified. Clinical translation may be accelerated by accruing experience with MIF-directed therapies currently in human testing in cancer and autoimmunity.Entities:
Keywords: Atherosclerosis; CD74; CXCR2; CXCR4; D-dopachrome tautomerase; ischemia reperfusion; macrophage migration inhibitory factor; myocardial infarction
Mesh：
Substances：
Year: 2017 PMID： 28562118 PMCID： PMC6130320 DOI： 10.1080/14728222.2017.1336227
Source DB: PubMed Journal: Expert Opin Ther Targets ISSN： 1472-8222 Impact factor: 6.902